Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cemiplimab + ISA101b in recurrent/metastatic HPV16-positive cervical cancer after first-line chemotherapy
NL-OMON54112Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and SLP-HPV-01 in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC) and cervical adenocarcinoma, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective response rate. Started Jan 2022; status: active, not recruiting.
02
Drugs
cemiplimabSLP-HPV-01
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)cervical adenocarcinoma
Beyond the preview
Go deeper on NL-OMON54112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54112.